<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868760</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI310G101</org_study_id>
    <nct_id>NCT04868760</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers</brief_title>
  <official_title>Compare IBI310 and Ipilimumab on the Pharmacokinetics, Safety, Tolerance and Immunogenicity of a Single Dose In Healthy Male Subjects: a Randomized Double-blind Parallel Controlled Phase I Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trail will investigate the pharmacokinetics and safety of IBI310 and establish&#xD;
      pharmacokinetics biosimilarity of IBI310 to ipilimumab （YERVOY）&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">December 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 5, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC0-inf)</measure>
    <time_frame>From pre-dose to 1848hrs (78day)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>From pre-dose to 1848hrs (78day)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve</measure>
    <time_frame>From pre-dose to 1848hrs (78day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>From pre-dose to 1848hrs (78day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>From pre-dose to 1848hrs (78day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of ADA and Nab</measure>
    <time_frame>From pre-dose to 1848hrs (78day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and severity of adverse events</measure>
    <time_frame>from dosing to completion of study (183days posy-dosing) or to the patient withdrawl</time_frame>
    <description>Number of subjects with AE，treatment-related AE (TRAE), immune-related AEs (irAE), serious adverse SAE assessed by CTCAE V5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Group B: ipilimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ipilimumab, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A: IBI310</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI 310, 0.1 and 0.3mg/kg, will be administrated intravenously in 30-60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Drug: Ipilimumab 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.</description>
    <arm_group_label>Group B: ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI310</intervention_name>
    <description>Drug: IBI310 0.1 mg/kg and 0.3 mg/kg in preparatory experiments and 0.3 mg/kg in formal experiment.</description>
    <arm_group_label>Group A: IBI310</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for the study, patients should fulfill all the following criteria:&#xD;
&#xD;
          1. Fully understand the study purpose, and understand the pharmacological effects and&#xD;
             potential adverse reactions of the drug, voluntarily signed written informed consent&#xD;
             according to the declaration of Helsinki.&#xD;
&#xD;
          2. Aged 18-55 years healthy male subjects&#xD;
&#xD;
          3. Weigh ranges from 50-80 kg， BMI ranges from 19.0-28.0 kg/m2&#xD;
&#xD;
          4. All the system test result within the normal range, or abnormal test results without&#xD;
             clinical significance judged by the investigator.&#xD;
&#xD;
          5. The subjects must agree to use effective contraceptive measures during the study&#xD;
             treatment and for 6 months after receiving last does of study drug (e.g. abstinence,&#xD;
             sterilization surgery, oral contraceptives, contraception by progesterone injection or&#xD;
             subcutaneous)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients should not enter the study if any of the following exclusion criteria are&#xD;
        fulfilled:&#xD;
&#xD;
          1. Medical history of chronic liver, kidney, cardiovascular, neurological/psychiatric,&#xD;
             digestive tract, respiratory, urinary, endocrine and other system diseases;&#xD;
&#xD;
          2. Medical history of autoimmune diseases (see Annex 1);&#xD;
&#xD;
          3. People who drink frequently in the 6 months before screening (the definition of&#xD;
             frequent drinking is defined as drinking more than 2 units per day on average, or&#xD;
             drinking more than 14 units of alcohol per week on average: 1 unit = 360ml of beer or&#xD;
             45ml of alcohol is 40 % Of spirits or 150ml wine);&#xD;
&#xD;
          4. Have opportunistic infections within 6 months before screening (such as: herpes&#xD;
             zoster, active cytomegalovirus, pneumocystis carinii, histoplasma, aspergillus,&#xD;
             mycobacterium, etc.)&#xD;
&#xD;
          5. Medical history of recurrence or chronic infection, have had chronic or recurrent&#xD;
             infections, including but not limited to: chronic kidney infection, chronic chest&#xD;
             infection (such as bronchiectasis), sinusitis, recurrent urinary tract infections,&#xD;
             those with open, draining or infected skin wounds;&#xD;
&#xD;
          6. Acute infection within 2 weeks before screening;&#xD;
&#xD;
          7. Medical history of malignant tumors, unless they are squamous cell carcinoma of the&#xD;
             skin, basal cell carcinoma or local cervical carcinoma in situ that have been&#xD;
             successfully removed and have no evidence of metastasis;&#xD;
&#xD;
          8. Suspected or confirmed to be allergic or have experienced severe drug or food allergic&#xD;
             reactions in the past, have clear history of allergies and/or are allergic to test&#xD;
             drugs or their ingredients;&#xD;
&#xD;
          9. Any drugs (including Chinese medicines and vitamins) have been used within 2 weeks&#xD;
             before the screening, or the last dose is less than 5 half-lives of the drug from the&#xD;
             trial dosing day, whichever is longe;&#xD;
&#xD;
         10. Any prior using of ipilimumab;&#xD;
&#xD;
         11. Participation in any other interventional clinical trials within 3 months before&#xD;
             screening;&#xD;
&#xD;
         12. Subjects have made a blood donation or a comparable blood lossor received any blood&#xD;
             transfusion (&gt;400 mL) within the last 3 months prior to screening.&#xD;
&#xD;
         13. Subjects underwent major surgery or hospitalization for illness within 3 months before&#xD;
             screening;&#xD;
&#xD;
         14. Subjects have received live vaccines within 6 months prior to screening, or expect to&#xD;
             receive live vaccines during the study period;&#xD;
&#xD;
         15. Any drug abuse or positive drug screening result within 12 months before screening;&#xD;
&#xD;
         16. Any abnormalities of vital signs and physical examination with clinical significance&#xD;
             as judged by investigators at screening;&#xD;
&#xD;
         17. Abnormalities in the ECG with clinicavl significance judged by investigators at&#xD;
             screening;&#xD;
&#xD;
         18. Abnormalities of chest-X ray or CT examination with clinical significance as judged by&#xD;
             investigators at screening;&#xD;
&#xD;
         19. Abnormal laboratory tests with clinical significance at screening.&#xD;
&#xD;
         20. Known Tuberculosis (TB) disease, high risk of acquiring TB infection, or latent TB&#xD;
             infection (including but not limited to tuberculosis, lymphatic tuberculosis,&#xD;
             tuberculous pleurisy, etc.), tuberculosis laboratory examination (QuantiFERON-TB&#xD;
             tuberculosis test/T.SPOT tuberculosis test) is positive.&#xD;
&#xD;
         21. Human Immunodeficiency Virus (HIV) antibody, Hepatitis C virus (HCV) antibody,&#xD;
             Syphilis test (RPR), Hepatitis B virus (HBV) surface antigen, e antigen ( HBeAg) or&#xD;
             core antibody (HBcAb) is positive;&#xD;
&#xD;
         22. Have a childbirth plan within 6 months from the screening period to the trial drug&#xD;
             administration, or who are unwilling to take the contraceptive measures specified in&#xD;
             the protocol during the trial period;&#xD;
&#xD;
         23. It is not suitable to participate in this clinical trial due to other reasons per&#xD;
             investigator discretion&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhang Jing</last_name>
    <phone>021-52887926</phone>
    <email>13816357098@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huashan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Jing</last_name>
      <phone>021-52887926</phone>
      <email>13816357098@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

